Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W3119085584', 'doi': 'https://doi.org/10.1093/ofid/ofaa515.1900', 'title': 'LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study', 'display_name': 'LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study', 'publication_year': 2020, 'publication_date': '2020-10-01', 'ids': {'openalex': 'https://openalex.org/W3119085584', 'doi': 'https://doi.org/10.1093/ofid/ofaa515.1900', 'mag': '3119085584'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/ofid/ofaa515.1900', 'pdf_url': 'https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S844/35339669/ofaa515.1900.pdf', 'source': {'id': 'https://openalex.org/S2735126445', 'display_name': 'Open Forum Infectious Diseases', 'issn_l': '2328-8957', 'issn': ['2328-8957'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': True, 'oa_status': 'gold', 'oa_url': 'https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S844/35339669/ofaa515.1900.pdf', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5066493413', 'display_name': 'Lori A Muir', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Lori A Muir', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5070317990', 'display_name': 'Susannah M. Walpole', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Susannah M Walpole', 'raw_affiliation_strings': ['Spero Therapeutics, Inc., Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Inc., Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5075915340', 'display_name': 'Patricia A Warfel', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Patricia A Warfel', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5054740762', 'display_name': 'Hanna Kwak', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Hanna Kwak', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5084536861', 'display_name': 'Anne-Marie Phelan', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Anne-Marie Phelan', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5076899486', 'display_name': 'Gary E Moore', 'orcid': None}, 'institutions': [], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Gary E Moore', 'raw_affiliation_strings': ['Moore Computing Services, Inc., Little Rock, Arkansas'], 'affiliations': [{'raw_affiliation_string': 'Moore Computing Services, Inc., Little Rock, Arkansas', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5101918664', 'display_name': 'Akash Jain', 'orcid': 'https://orcid.org/0000-0002-3601-7571'}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Akash Jain', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5073727182', 'display_name': 'Tim Keutzer', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Tim Keutzer', 'raw_affiliation_strings': ['Spero Therapeutics, inc, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, inc, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5030399565', 'display_name': 'Aaron Dane', 'orcid': 'https://orcid.org/0000-0002-2997-4074'}, 'institutions': [], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Aaron Dane', 'raw_affiliation_strings': ['DaneStat Consulting, Macclesfield, Cheshire, England, United Kingdom'], 'affiliations': [{'raw_affiliation_string': 'DaneStat Consulting, Macclesfield, Cheshire, England, United Kingdom', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5030399565', 'display_name': 'Aaron Dane', 'orcid': 'https://orcid.org/0000-0002-2997-4074'}, 'institutions': [], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Aaron Dane', 'raw_affiliation_strings': ['DaneStat Consulting, Macclesfield, Cheshire, England, United Kingdom'], 'affiliations': [{'raw_affiliation_string': 'DaneStat Consulting, Macclesfield, Cheshire, England, United Kingdom', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5060861947', 'display_name': 'David Melnick', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'David Melnick', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5108773992', 'display_name': 'Angela K. Talley', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210160063', 'display_name': 'Spero Therapeutics (United States)', 'ror': 'https://ror.org/05fxq1221', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I4210160063']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Angela K Talley', 'raw_affiliation_strings': ['Spero Therapeutics, Cambridge, Massachusetts'], 'affiliations': [{'raw_affiliation_string': 'Spero Therapeutics, Cambridge, Massachusetts', 'institution_ids': ['https://openalex.org/I4210160063']}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': {'value': 3064, 'currency': 'USD', 'value_usd': 3064, 'provenance': 'doaj'}, 'apc_paid': {'value': 3064, 'currency': 'USD', 'value_usd': 3064, 'provenance': 'doaj'}, 'fwci': 1.213, 'has_fulltext': True, 'fulltext_origin': 'pdf', 'cited_by_count': 9, 'citation_normalized_percentile': {'value': 0.656918, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 85, 'max': 86}, 'biblio': {'volume': '7', 'issue': 'Supplement_1', 'first_page': 'S844', 'last_page': 'S845'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11036', 'display_name': 'Antibiotics Pharmacokinetics and Efficacy', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11036', 'display_name': 'Antibiotics Pharmacokinetics and Efficacy', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2736', 'display_name': 'Pharmacology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10147', 'display_name': 'Antibiotic Resistance in Bacteria', 'score': 0.9989, 'subfield': {'id': 'https://openalex.org/subfields/1313', 'display_name': 'Molecular Medicine'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T11232', 'display_name': 'Urinary Tract Infections Management', 'score': 0.9982, 'subfield': {'id': 'https://openalex.org/subfields/2713', 'display_name': 'Epidemiology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/ertapenem', 'display_name': 'Ertapenem', 'score': 0.94940597}, {'id': 'https://openalex.org/keywords/carbapenem', 'display_name': 'Carbapenem', 'score': 0.6836612}], 'concepts': [{'id': 'https://openalex.org/C2778368673', 'wikidata': 'https://www.wikidata.org/wiki/Q553220', 'display_name': 'Ertapenem', 'level': 5, 'score': 0.94940597}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.8947083}, {'id': 'https://openalex.org/C2776685102', 'wikidata': 'https://www.wikidata.org/wiki/Q410897', 'display_name': 'Carbapenem', 'level': 3, 'score': 0.6836612}, {'id': 'https://openalex.org/C27081682', 'wikidata': 'https://www.wikidata.org/wiki/Q269829', 'display_name': 'Placebo', 'level': 3, 'score': 0.5476035}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.51798666}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.49834156}, {'id': 'https://openalex.org/C2908647359', 'wikidata': 'https://www.wikidata.org/wiki/Q2625603', 'display_name': 'Population', 'level': 2, 'score': 0.46069854}, {'id': 'https://openalex.org/C90924648', 'wikidata': 'https://www.wikidata.org/wiki/Q120569', 'display_name': 'Gastroenterology', 'level': 1, 'score': 0.42054382}, {'id': 'https://openalex.org/C126894567', 'wikidata': 'https://www.wikidata.org/wiki/Q105650', 'display_name': 'Urology', 'level': 1, 'score': 0.39199108}, {'id': 'https://openalex.org/C2779375183', 'wikidata': 'https://www.wikidata.org/wiki/Q421670', 'display_name': 'Meropenem', 'level': 4, 'score': 0.30581072}, {'id': 'https://openalex.org/C501593827', 'wikidata': 'https://www.wikidata.org/wiki/Q12187', 'display_name': 'Antibiotics', 'level': 2, 'score': 0.21108866}, {'id': 'https://openalex.org/C94665300', 'wikidata': 'https://www.wikidata.org/wiki/Q63391344', 'display_name': 'Antibiotic resistance', 'level': 3, 'score': 0.15554675}, {'id': 'https://openalex.org/C89423630', 'wikidata': 'https://www.wikidata.org/wiki/Q7193', 'display_name': 'Microbiology', 'level': 1, 'score': 0.11231774}, {'id': 'https://openalex.org/C204787440', 'wikidata': 'https://www.wikidata.org/wiki/Q188504', 'display_name': 'Alternative medicine', 'level': 2, 'score': 0.0}, {'id': 'https://openalex.org/C99454951', 'wikidata': 'https://www.wikidata.org/wiki/Q932068', 'display_name': 'Environmental health', 'level': 1, 'score': 0.0}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.0}, {'id': 'https://openalex.org/C142724271', 'wikidata': 'https://www.wikidata.org/wiki/Q7208', 'display_name': 'Pathology', 'level': 1, 'score': 0.0}], 'mesh': [], 'locations_count': 3, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/ofid/ofaa515.1900', 'pdf_url': 'https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S844/35339669/ofaa515.1900.pdf', 'source': {'id': 'https://openalex.org/S2735126445', 'display_name': 'Open Forum Infectious Diseases', 'issn_l': '2328-8957', 'issn': ['2328-8957'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': True, 'landing_page_url': 'https://europepmc.org/articles/pmc7776701', 'pdf_url': 'https://europepmc.org/articles/pmc7776701?pdf=render', 'source': {'id': 'https://openalex.org/S4306400806', 'display_name': 'Europe PMC (PubMed Central)', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1303153112', 'host_organization_name': 'European Bioinformatics Institute', 'host_organization_lineage': ['https://openalex.org/I1303153112'], 'host_organization_lineage_names': ['European Bioinformatics Institute'], 'type': 'repository'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, {'is_oa': True, 'landing_page_url': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776701', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764455111', 'display_name': 'PubMed Central', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': 'acceptedVersion', 'is_accepted': True, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.1093/ofid/ofaa515.1900', 'pdf_url': 'https://academic.oup.com/ofid/article-pdf/7/Supplement_1/S844/35339669/ofaa515.1900.pdf', 'source': {'id': 'https://openalex.org/S2735126445', 'display_name': 'Open Forum Infectious Diseases', 'issn_l': '2328-8957', 'issn': ['2328-8957'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310311648', 'host_organization_name': 'Oxford University Press', 'host_organization_lineage': ['https://openalex.org/P4310311647', 'https://openalex.org/P4310311648'], 'host_organization_lineage_names': ['University of Oxford', 'Oxford University Press'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'score': 0.78, 'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4377987402', 'https://openalex.org/W4282834160', 'https://openalex.org/W4224222524', 'https://openalex.org/W2595667698', 'https://openalex.org/W2522250029', 'https://openalex.org/W2285087135', 'https://openalex.org/W2184417017', 'https://openalex.org/W2002728592', 'https://openalex.org/W1991087639', 'https://openalex.org/W1720517915'], 'abstract_inverted_index': {'Abstract': [0], 'Background': [1], 'Tebipenem': [2, 21], 'pivoxil': [3], 'hydrobromide': [4], '(TBP-PI-HBr)': [5, 293], 'is': [6, 12, 39], 'an': [7, 163, 291, 297], 'orally': [8], 'bioavailable': [9], 'prodrug': [10], 'that': [11], 'rapidly': [13], 'converted': [14], 'in': [15, 23, 42, 78, 107, 145, 192, 217, 253, 260, 301, 314], 'plasma': [16], 'to': [17, 66, 116, 142, 296], 'the': [18, 43, 47, 68, 99, 108, 153, 254, 261, 284, 315, 327], 'carbapenem,': [19], 'tebipenem.': [20], 'has': [22], 'vitro': [24], 'activity': [25], 'against': [26], 'select': [27], 'multidrug-resistant': [28], 'Gram-negative': [29, 336], 'pathogens,': [30], 'including': [31], 'fluoroquinolone-resistant': [32], 'and': [33, 55, 70, 95, 220, 244, 305, 326], 'extended-spectrum': [34], 'ß-lactamase': [35], '(ESBL)-producing': [36], 'Enterobacterales.': [37], 'TBP-PI-HBr': [38, 74, 118, 151, 207, 219, 255, 317], 'being': [40], 'developed': [41], 'United': [44], 'States': [45], 'as': [46], 'first': [48, 285, 328], 'oral': [49, 73, 134, 292, 322, 329], 'carbapenem': [50, 330], 'for': [51, 137, 199, 332], 'treatment': [52, 194, 205], 'of': [53, 72, 156, 167, 230, 288, 290], 'cUTI': [54, 83, 304], 'AP.': [56, 85], 'Methods': [57], 'ADAPT-PO': [58], 'was': [59, 89, 208, 233], 'a': [60, 308, 320], 'global,': [61], 'double-blind,': [62], 'Phase': [63, 280], '3': [64, 257, 281], 'study': [65, 231, 282], 'evaluate': [67], 'efficacy': [69], 'safety': [71], 'vs.': [75, 170, 270], 'IV': [76, 125, 131, 160, 298], 'ertapenem': [77, 128, 161, 222, 262], 'hospitalized': [79], 'adult': [80], 'patients': [81, 146, 302, 333], 'with': [82, 147, 159, 162, 272, 303, 307, 334], 'or': [84, 127], 'The': [86, 237], 'primary': [87, 154], 'endpoint': [88], 'overall': [90, 164], 'response': [91, 165, 197], '(composite': [92], 'clinical': [93], 'cure': [94, 185], 'microbiologic': [96], 'eradication)': [97], 'at': [98, 187], 'test-of-cure': [100], '(TOC)': [101], 'visit': [102], '(Day': [103], '19': [104], '±': [105], '2)': [106], 'micro-ITT': [109], 'population.': [110], 'Patients': [111], '(N=1372)': [112], 'were': [113, 189, 202, 215, 226, 241, 251, 267], 'randomized': [114], '1:1': [115], 'receive': [117], '600': [119], 'mg': [120], 'PO': [121], 'q8h': [122, 136], 'plus': [123, 133], 'placebo': [124, 135], 'q24h': [126, 132], '1': [129], 'g': [130], '7–10': [138], 'days': [139, 144], '(or': [140], 'up': [141], '14': [143], 'bacteremia).': [148], 'Results': [149, 276], 'Oral': [150], 'met': [152], 'objective': [155], 'non-inferiority': [157, 289], 'compared': [158], 'rate': [166], '58.8%': [168], '(264/449)': [169], '61.6%': [171], '(258/419),': [172], 'respectively': [173], '(treatment': [174], 'difference': [175], '-3.3%;': [176], '95%': [177], 'CI:': [178], '-9.7,': [179], '3.2;': [180], '-12.5%': [181], 'NI': [182], 'margin).': [183], 'Clinical': [184], 'rates': [186, 198], 'TOC': [188], '>': [190], '93%': [191], 'both': [193], 'groups.': [195, 206], 'Microbiological': [196], 'target': [200], 'uropathogens': [201], 'comparable': [203, 309], 'across': [204], 'well': [209], 'tolerated.': [210], 'Treatment-emergent': [211], 'adverse': [212, 265], 'events': [213, 266], '(TEAEs)': [214], 'observed': [216, 252], '25.7%': [218], '25.6%': [221], 'patients.': [223], 'Most': [224], 'TEAEs': [225, 240, 250], 'mild;': [227], 'premature': [228], 'discontinuation': [229], 'drug': [232], 'uncommon': [234], '(<': [235], '1%).': [236], 'most': [238], 'frequent': [239], 'diarrhea': [242], '(5.0%)': [243], 'headache': [245], '(3.8%).': [246], 'No': [247], 'C.': [248], 'difficile-associated': [249], 'group;': [256], 'cases': [258], 'occurred': [259], 'group.': [263], 'Serious': [264], 'infrequent': [268], '(1.3%': [269], '1.7%),': [271], 'no': [273], 'deaths.': [274], 'Conclusion': [275], 'from': [277], 'this': [278], 'pivotal': [279], 'provide': [283, 319], 'head-to-head': [286], 'demonstration': [287], 'antibacterial': [294], 'agent': [295, 300], '(ertapenem)': [299], 'AP,': [306], 'tolerability': [310], 'profile.': [311], 'If': [312], 'approved': [313], 'U.S.,': [316], 'would': [318], 'new': [321], 'therapeutic': [323], 'option': [324], '—': [325, 331], 'serious': [335], 'infections.': [337], 'Disclosures': [338], 'Lori': [339], 'A.': [340], 'Muir,': [341], 'n/a,': [342, 359, 365], 'Spero': [343, 353, 360, 366, 376, 382, 388, 403, 409, 418], 'Therapeutics': [344, 346, 361, 367, 369, 377, 383, 410, 412, 419], '(Employee)Spero': [345, 368, 411], '(Employee,': [347, 370, 420], 'Shareholder)': [348, 371, 421], 'Susannah': [349], 'M.': [350], 'Walpole,': [351], 'PhD,': [352, 381], 'Therapeutics,': [354, 389], 'Inc.': [355], '(Employee)': [356, 362, 384, 391, 413], 'Hanna': [357], 'Kwak,': [358], 'Anne-Marie': [363], 'Phelan,': [364], 'Gary': [372], 'E.': [373], 'Moore,': [374], 'BS/MS,': [375], '(Consultant)': [378, 399, 405], 'Akash': [379], 'Jain,': [380], 'Tim': [385], 'Keutzer,': [386], 'BA,': [387], 'Inc': [390], 'Aaron': [392, 400], 'Dane,': [393, 401], 'MSc,': [394, 402], 'Da': [395], 'Volterra': [396], '(Consultant)Spero': [397], 'theraputics': [398, 404], 'David': [406], 'Melnick,': [407], 'MD,': [408, 417], 'Angela': [414], 'K.': [415], 'Talley,': [416]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3119085584', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2022, 'cited_by_count': 3}, {'year': 2021, 'cited_by_count': 5}], 'updated_date': '2024-12-24T06:26:01.693436', 'created_date': '2021-01-18'}